Figure 6.

Effect of oclacitinib (OCL) on the proliferation of CD4⁺ (A) and CD8⁺ (B) T cells. The relative count of 5-bromo-2’-deoxyuridine(BrdU)-incorporating cells among CD4⁺ and CD8⁺ T cells was determined in cell cultures incubated with or without (control) OCL (10⁻⁶ M and 10⁻⁷ M). Results are the mean (± S.D.) of three independent experiments with 5 mice per experiment (overall n = 15, * p < 0.001, control cells vs OCL-treated (10⁻⁶ or 10⁻⁷ M) cells (Student’s unpaired t-test)). Examples of dot plot cytograms show the distribution of BrdU-positive and -negative cells within CD4⁺ and CD8⁺ T cell subsets (C). Fluorescence minus one (FMO) controls as well as cultured cells without BrdU were used to confirm the gating strategy used to identify BrdU⁺ cells. Cells treated with mycophenolic acid (MPA, an active metabolite of the prodrug mycophenolate mofetil), i.e., the agent with the proved antiproliferative activity to T cells, constituted an additional negative as well as a reference control.